2,788 press releases indexed under education.
LINKÖPING, Sweden, Aug. 19, 2026 /PRNewswire/ -- International medical imaging IT and cybersecurity company Sectra (STO: SECT B) will provide its cloud-based Education Portal to Loyalist College in Ontario, Canada. The platform will give students access to anonymized diagnostic imaging...
GUANGZHOU, China, Aug. 19, 2026 /PRNewswire/ -- As the back-to-school shopping season gains momentum, demand for stationery, learning tools, and educational technology products is on the rise. As one of the most essential items in students' daily learning routines, writing instruments...
HONG KONG, August 19, 2026 - (ACN Newswire) - Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157% year-on-year to RMB 1.148 billion, driven by continued commercial momentum across the company’s portfolio. Gross margin excluding non-cash items reached 73.7%, while operating expenses as a percentage of revenue decreased by 64.0 percentage points year-on-year, reflecting increasing operating leverage and execution efficiency. From the first-half results, the company’s growth drivers are broadening beyond the commercialization of core products to include portfolio expansion, monetization of innovative assets, and global expansion. In the first half of 2026, the company achieved non-IFRS net profit of RMB 97.23 million, while IFRS net loss narrowed by 98% year-on-year. Everest ended the period with RMB 1.859 billion in cash. Following the reporting period, the company received approximately RMB 770 million in July from the upfront payment under its global licensing and collaboration agreement for civorebrutinib, further strengthening its financial position and capacity to invest in future growth. Mr. Yifang Wu, Chairman of the Board of Everest Medicines, said: “Everest Medicines has entered a new phase of development as an innovation-driven, integrated biopharmaceutical company. Guided by our 2030 Strategy, we are strengthening our capabilities in innovation, commercialization, and global development, accelerating the realization of global value and laying a stronger foundation for sustainable, high-quality growth.” During the period, the company achieved profitability, while expanding its innovative pipeline and advancing its R&D programs. Through continued efforts to strengthen its BD capabilities, the company is developing a model that combines in-licensed and internally developed early-stage assets, exemplified by civorebrutinib (also known as EVER001), with internal incubation and development creating opportunities to out-license innovative assets and realize their value. At the same time, the company is bringing in high-quality mid- to late-stage assets, exemplified by NEFECON(R), while continuing to build its commercialization capabilities and generate further opportunities for BD partnerships. These efforts are enhancing the efficiency of innovation resource allocation and accelerating the translation of innovation into clinical and commercial value. Everest’s marketed portfolio continued to gain momentum NEFECON(R) maintained strong sales momentum. In the first half of 2026, sales revenue from NEFECON(R) reached RMB 889 million, with net sales increasing 94% year-on-year. Through deeper penetration across key hospitals, broader market expansion, enhanced physician and patient education, and continued generation of real-world evidence, Everest is supporting broader adoption of treatment strategies focused on addressing underlying causes, early intervention, and long-term management. Following approval, VELSIPITY(R) moved rapidly into commercialization, with local manufacturing progressing. XERAVA(R) delivered steady hospital sales growth, while local manufacturing advanced as planned. The company also reached an understanding with Hainan Herui Pharmaceutical Co., Ltd. regarding certain NEFECON(R)-related patent matters and entered into a commercialization collaboration for budesonide enteric capsules, further broadening treatment options for patients. Meanwhile, commercialization services for Hasten Biopharmaceuticals continued to contribute to revenue growth. Services for mature products under the CSO arrangement commenced in March 2026, generating RMB 145 million in service revenue and RMB 28 million in commercialization profit in the first half of the year. Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines, said: “In the first half of 2026, the company continued to execute its strategy and accelerate the translation of innovation into clinical and commercial value. Solid progress across commercialization, BD, in-house R&D, and global expansion further strengthened our foundation for sustainable growth and our ability to bring innovative therapies to patients. Our BD strategy is building a diversified portfolio of future growth drivers through global partnerships for internally developed assets and selective in-licensing of differentiated innovative assets, while our in-house R&D continues to generate clinical progress. With the establishment of a pan-Asia-Pacific commercialization platform, we are also extending our proven capabilities from China into other Asian markets.” EVER001 global licensing deal expected to accelerate overseas development In June, the company entered into an exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also known as EVER001) in all markets outside China and certain countries in East and Southeast Asia. The deal has a total potential value of up to $1.1425 billion, including an upfront payment of $112.5 million and up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. CICC believes the partnership is expected to accelerate the global clinical development and commercialization of EVER001 and could advance its development in membranous nephropathy. BOCOM International is positive on EVER001’s overseas market potential and its development opportunities across additional indications. EVER001 achieved positive 52-week Phase 1b/2a clinical results, and a Phase 2 basket trial has been initiated in China to further evaluate its potential in autoimmune kidney diseases, including FSGS, MCD, and IgAN. BD expansion further strengthens the product pipeline The company continued to selectively introduce mid- to late-stage assets with strong commercial potential. MT1013, DMX-200, and Bejescin(R) strengthened its nephrology and autoimmune portfolio; CARDAMYST(R) and Sumecigrel (formerly known as Vicagrel) further expanded its cardiovascular portfolio; and LNZ100, together with VIS-101, enhanced its ophthalmology portfolio. With multiple assets moving through key regulatory and commercialization milestones, the company is building a diversified portfolio of future growth drivers. CARDAMYST(R) is expected to receive approval in the third quarter of 2026, LEROCHOL(R) and LNZ100 are expected to receive approval in 2027, and MT1013 is expected to receive approval in 2028. In-house R&D and pan-Asia-Pacific expansion advance The company’s in-house R&D also translated into clinical progress. The company’s proprietary AI+mRNA platform also advanced, with its personalized mRNA cancer vaccine EVM16 achieving its first-in-human clinical data readout and planned to enter an investigator-initiated Phase 1b study in the fourth quarter of 2026. EVM18, the company’s in vivo CAR-T therapy, has initiated IIT studies across multiple autoimmune diseases and is advancing toward global IND filings. The acquisition of Hasten Biopharmaceuticals (SG) Pte. Ltd. further strengthened the company’s global commercialization capabilities and established a pan-Asia-Pacific commercialization platform. The platform provides a foundation for scaling the company’s proven commercialization capabilities from China across Asian markets, supporting the regional expansion of both existing and future products. Meanwhile, CBC Group and the company’s Directors have collectively purchased 5.163 million shares since December 2025, with the transactions totaling more than HK$172.5 million, demonstrating their confidence in the company’s strategic direction and long-term prospects. Overall, Everest Medicines is gradually developing a growth model built on the commercialization of core products, portfolio expansion through BD, a pipeline of innovative assets generated through in-house R&D, and international expansion through global partnerships and its pan-Asia-Pacific platform. As the company enters its new phase, the coordinated strengthening of its capabilities in innovation resource integration, commercialization, and global development is expected to provide an important foundation for future growth. Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
APOD Science APOD APOD: 2026 August 19 – The… Today’s APOD Archive Submissions Index Search Calendar RSS Education About Discuss APOD Astronomy Picture of the Day Discover the cosmos! Each day a different image or photograph of our fascinating universe is featured, along with a brief explanation written by a professional astronomer. To view […]
LONDON, Aug 19, 2026 - (ACN Newswire) - Aurentis Capital Group has announced a technology-driven trading platform designed to provide market participants with access to a range of global financial instruments through a streamlined digital environment. The platform is designed around the needs of traders seeking access to markets including equities, commodities, currencies and indices. Aurentis Capital said its approach combines market access with digital tools intended to support market monitoring, analysis and account management. Platform Designed for Multi-Asset Market Access Aurentis Capital Group's platform brings multiple financial markets together within a single trading environment. The offering is intended to allow users to monitor market movements, review positions and manage trading activity through digital devices. The company said the platform has been developed with an emphasis on accessibility and ease of use, with functionality available across desktop and mobile environments. Focus on Trading Technology The platform incorporates market-monitoring and analytical functionality intended to support traders as they assess changing market conditions. Features include market data, charting capabilities and account-management tools. The company said the technology is intended to provide traders with a centralized environment for monitoring markets and managing their trading activity. Educational and Analytical Resources Alongside its trading technology, Aurentis Capital provides educational and analytical resources covering financial markets and trading-related topics. The resources are intended to support users in developing their understanding of market structure, trading strategies and risk-management principles. Educational materials may include market commentary, tutorials, analytical resources and other learning content, subject to availability through the platform. Risk and Market Considerations Trading financial instruments, particularly leveraged products such as Contracts for Difference (CFDs), involves significant risk and may not be suitable for all investors. Market prices can move rapidly, and losses can occur. Depending on the product, leverage and applicable jurisdiction, losses may exceed the initial amount invested. Prospective clients should review the applicable product documentation, terms and risk disclosures before trading and should consider whether the products are appropriate for their individual circumstances. Where appropriate, independent financial advice should be obtained. About Aurentis Capital Group Aurentis Capital (https://aurentiscg.com) is a financial-services brand focused on providing technology-enabled access to global financial markets. The company develops its offering around digital trading infrastructure, market access and resources intended to support market participants. Media contact Brand: Aurentis Capital Group Contact: Media team Website: https://aurentiscg.com Copyright 2026 ACN Newswire. All rights reserved. www.acnnewswire.com
IRVINE, Calif., August 18, 2026--Phoenix Energy has announced that founder and Phoenix Energy CEO Adam Ferrari has been selected to receive the 2026 Young Alumni Achievement Award from the University of Illinois Urbana-Champaign Department of Chemical & Biomolecular Engineering.
Smart Savings for Busy Families
BALTIMORE, Aug. 18, 2026 (GLOBE NEWSWIRE) -- MarketWise, Inc. (NASDAQ: MKTW) (“MarketWise” or “the Company”), a leading multi-brand digital subscription services platform that provides premium financial research, software, education, and tools for self-directed investors, today announced that Chief Operating and Financial Officer, Erik Mickels, will host virtual meetings at the UBS SMID-Cap Multisector Virtual Conference on Thursday, September 24, 2026.
The Connecticut-based nonprofit will offer online credential, certificate, and degree programs to eligible Vermont residents who participate in the 3SquaresVT program. EAST HARTFORD, Conn., Aug. 18, 2026 /PRNewswire/ -- Goodwin University, a nonprofit university located in East Hartford,...
Among 5,419 respondents, responsible use was the top learning topic at 52%, while 59% want real examples from their field, priorities that align with the University's existing academic AI framework for responsible, applied learning. PHOENIX, Aug. 18, 2026 /PRNewswire/ -- As artificial...
'Extraordinary generosity' establishes the Sallyport Fellows Program and supports Gateway Project HOUSTON, Aug. 18, 2026 /PRNewswire/ -- Rice University has received a $25 million gift from university trustee James "Jim" Whitehurst '89 and his wife, Lauren Whitehurst, to establish the...